Pα+ Psychedelic Bulletin #207
- Lykos Rebrands to Resilient
- Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision
- AbbVie-Gilgamesh Deal Viewed as Validation
- Psilocybin Rescheduling Petition Heads to HHS
- Much, much more...
psychedelicalpha.com/news/p%ce%b1...
psychedelicalpha.com
Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •